H. Lundbeck A/S (LON:0ND5)
London
· Delayed Price · Currency is GBP · Price in DKK | Market Cap | 4.35B |
| Revenue (ttm) | 2.57B |
| Net Income (ttm) | 368.84M |
| Shares Out | n/a |
| EPS (ttm) | 0.37 |
| PE Ratio | 11.78 |
| Forward PE | 7.26 |
| Dividend | 0.11 (0.27%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 22,558 |
| Average Volume | 36,409 |
| Open | 39.50 |
| Previous Close | 39.48 |
| Day's Range | 39.16 - 39.74 |
| 52-Week Range | 27.20 - 49.38 |
| Beta | n/a |
| RSI | 71.83 |
| Earnings Date | Aug 20, 2025 |
About H. Lundbeck
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]
Financial Performance
In 2024, H. Lundbeck's revenue was 22.00 billion, an increase of 10.51% compared to the previous year's 19.91 billion. Earnings were 3.14 billion, an increase of 37.25%.
Financial numbers in DKK Financial StatementsNews
Lundbeck Delivering On The Financials, But Needs Some Positive Clinical Drivers
Lundbeck's shares have declined due to U.S. policy risks and a perceived clinical setback, but core financial performance remains strong with solid Q1 results. Near-term upside hinges on regulatory su...
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a po...
Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade)
Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with successful clinical trials.